Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mitochondrial apoptosis machinery, also known as the intrinsic apoptosis pathway, is a sophisticated regulatory network of proteins that governs programmed cell death in response to intracellular stress signals such as DNA damage, oxidative stress, and growth factor deprivation [1, 3]. This machinery is primarily controlled by the B-cell lymphoma 2 (BCL-2) family of proteins, which consists of pro-apoptotic members (e.g., BAX, BAK) and anti-apoptotic members (e.g., BCL-2, BCL-XL, MCL-1) that maintain the integrity of the mitochondrial outer membrane [1, 6]. When the balance shifts toward a pro-apoptotic state, these proteins facilitate mitochondrial outer membrane permeabilization (MOMP), leading to the release of apoptogenic factors like cytochrome c and SMAC into the cytoplasm [2, 9]. Once in the cytosol, cytochrome c binds to Apaf-1 to form the apoptosome, which activates caspase-9 and initiates a proteolytic cascade that dismantles the cell [3, 13]. Dysregulation of this machinery is a hallmark of cancer, where overexpression of anti-apoptotic proteins allows malignant cells to evade death and develop resistance to therapy [1, 8]. Therapeutic strategies targeting this machinery, such as BH3 mimetics like venetoclax, aim to restore the apoptotic threshold and have shown significant clinical success, particularly in hematological malignancies [1, 6]. Beyond cancer, excessive activation of this machinery is implicated in neurodegenerative and cardiovascular diseases, where it contributes to pathological cell loss [7, 11].
The primary mechanism of action for drugs targeting this machinery involves the use of BH3 mimetics to antagonize anti-apoptotic B-cell lymphoma 2 (BCL-2) family members, which triggers mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome c, and the subsequent activation of the caspase cascade leading to apoptosis [1, 3, 6].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial apoptosis machinery.